Orgenesis Inc. entered into securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants for gross proceeds of $2,340,900.57 on March 3, 2024.The warrants are exercisable immediately and expire five years from the date of issuance. The transaction is expected to close on March 5, 2024. The securities to be sold in this private placement will not be registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold pursuant to Regulation D of the Securities Act.

The transaction will include participation from participation from healthcare industry executives and physicians.